Profil
Marc Chamberlain currently works at Lantern Pharma, Inc., as Chief Medical Officer-Starlight Therapeutics from 2023.
Dr. Chamberlain also formerly worked at Seagen, Inc., as Medical Director, Cascadian Therapeutics LLC, as Medical Director, Angiochem, Inc., as Medical Director, and Pionyr Immunotherapeutics, Inc., as Medical Director.
Postes actifs de Marc Chamberlain
| Sociétés | Poste | Début |
|---|---|---|
| LANTERN PHARMA INC. | Corporate Officer/Principal | 01/11/2023 |
Anciens postes connus de Marc Chamberlain
| Sociétés | Poste | Fin |
|---|---|---|
Angiochem, Inc.
Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for brain diseases | Corporate Officer/Principal | - |
| SEAGEN INC. | Corporate Officer/Principal | - |
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Develops antibody-based Immuno-oncology therapeutics | Corporate Officer/Principal | - |
| CASCADIAN THERAPEUTICS INC (USA) | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Seagen, Inc.
Seagen, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cancer medicines | Health Technology |
Cascadian Therapeutics LLC
Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Develops therapeutic products for the treatment of cancer | Health Technology |
Angiochem, Inc.
Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for brain diseases | Health Technology |
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Develops antibody-based Immuno-oncology therapeutics | Health Technology |
Lantern Pharma, Inc.
Lantern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drug from advanced genomics and artificial intelligence | Health Technology |
















